Respiratory Syncytial Virus Vaccine Market Report 2026

Respiratory Syncytial Virus Vaccine Market Overview

• The Respiratory Syncytial Virus Vaccine market growth in the historic period has been driven by rising incidence of rsv-related hospitalizations, unmet medical need in infant immunization • Market expansion is supported by increasing approval of novel rsv vaccines, growing government immunization funding • Growth Driver: Rising Respiratory Infections Fuel Growth In RSV Vaccine Market • Market Trend: Enhancing RSV Vaccine Efficacy Through Recombinant Protein Technology • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Respiratory Syncytial Virus Vaccine Market?

A respiratory syncytial virus (RSV) vaccine is a medical preparation designed to protect individuals, particularly infants, older adults, and high-risk populations, from severe respiratory infections caused by RSV. It works by stimulating the immune system to recognize and fight the virus, reducing the risk of hospitalization and severe disease. The main types of respiratory syncytial virus vaccines are viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine refers to a vaccine designed to prevent infections caused by viruses. It includes various indications, such as pediatric indications, geriatric indications, and high-risk individuals, and they are distributed through hospitals and other pharmacies and government suppliers.

What Is The Respiratory Syncytial Virus Vaccine Market Growth Forecast?

The respiratory syncytial virus vaccine market size is expected to see strong growth in the next few years. It will grow to $1957.68 million in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing approval of novel rsv vaccines, growing government immunization funding, rising adoption among elderly populations, expansion of preventive healthcare programs, increasing focus on combination vaccine development. Major trends in the forecast period include increasing development of rsv vaccines for high-risk populations, rising focus on pediatric and geriatric immunization programs, growing investment in advanced vaccine formulations, expansion of hospital-based vaccination campaigns, enhanced emphasis on long-term rsv prevention.

Global Respiratory Syncytial Virus Vaccine Market Segmentation

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine 2) By Clinical Indications: Pediatric Indication, Geriatric Indication, High-Risk Individuals 3) By Distribution Channel: Hospital And Others Pharmacies, Government Suppliers

What Is The Driver Of The Respiratory Syncytial Virus Vaccine Market?

The rising incidence of respiratory infections is expected to propel the growth of the respiratory syncytial virus vaccine market going forward. Respiratory infections are illnesses caused by viruses, bacteria, or other pathogens that affect the respiratory system, including the sinuses, throat, airways, or lungs. The rising incidence of respiratory infections is driven by factors such as air pollution, climate change, increased urbanization, aging populations, and the emergence of drug-resistant pathogens. The respiratory syncytial virus (RSV) vaccine helps mitigate the incidence of respiratory infections by preventing RSV-related illnesses, especially in vulnerable populations such as infants and older adults. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, the number of tuberculosis (TB) cases in England experienced a 10.7% year-over-year increase in 2023, rising from 4,380 cases in 2022 to 4,850 cases. Therefore, the rising incidence of respiratory infections will drive the growth of the respiratory syncytial virus vaccine industry.

Key Players In The Global Respiratory Syncytial Virus Vaccine Market

Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, Moderna Inc.

Global Respiratory Syncytial Virus Vaccine Market Trends and Insights

Major companies operating in the respiratory syncytial virus (RSV) vaccine market are focusing on developing innovative solutions, such as recombinant protein-based vaccine technologies, to meet the rising demand for high-efficacy vaccines, improved immune protection, and safer formulations for older adults at greater risk of RSV complications. Recombinant protein-based vaccines are created using genetically engineered proteins that mimic viral components, enabling strong, targeted immune responses without using live virus offering a more controlled and stable alternative to traditional vaccine approaches. For instance, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, received FDA approval for Arexvy, the first RSV vaccine designed to prevent lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy utilizes advanced recombinant protein technology to target the RSV fusion (F) protein, a critical viral component required for infection, providing robust protection for older adults.

What Are Latest Mergers And Acquisitions In The Respiratory Syncytial Virus Vaccine Market?

In February 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Icosavax, Inc., for $1.1 billion. This acquisition strengthens AstraZeneca's vaccines & immune therapies pipeline, with Icosavax's lead candidate, IVX-A12, targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), key pathogens responsible for severe respiratory infections in high-risk groups, including the elderly and individuals with chronic conditions. Icosavax, Inc. is a US-based clinical-stage biopharmaceutical company actively developing a respiratory syncytial virus (RSV) vaccine through its lead candidate, IVX-A12.

Regional Insights

North America was the largest region in the respiratory syncytial virus vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Respiratory Syncytial Virus Vaccine Market?

The respiratory syncytial virus vaccine market consists of sales of protein-based vaccines, mRNA vaccines, monoclonal antibodies, and live-attenuated vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Respiratory Syncytial Virus Vaccine Market Report 2026?

The respiratory syncytial virus vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.